Automate your daily routine with these 8 free AI agents that handle research, writing, document management, and more to boost ...

(NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA ® (tucatinib) in patients with ...